European Commission Approves Roche Drug For Age-Related Macular Degeneration
The European Commission has approved Roche Holding AG's Susvimo for the treatment of neovascular age-related macular degeneration (AMD).
Sept 21 (Reuters) — Roche Holding AG said the European Commission has approved Susvimo for the treatment of neovascular age-related macular degeneration (nAMD). The company said the phase III Archway study showed Susvimo maintained vision equivalent to monthly injections. com; +48 587785269;)